Researcher
Liese Barbier
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From20 Sep 2016 → Today
Projects
1 - 5 of 5
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Optimizing the conduct and implementation of patient preference research in drug development and evaluation: a focus on oncology and COVID-19From22 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Patient preferences in cardiology: methodological aspects and integration decision-makingFrom6 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Policy recommendations for a pharmaceutical R&D and evaluation framework that is driven by unmet medical needsFrom15 Sep 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Sustainable biosimilar competition: clinical, regulatory and policy insightsFrom20 Sep 2016 → 18 Nov 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 25
- Personalized and longitudinal electronic informed consent in clinical trials: How to move the needle?(2024)
Authors: Liese Barbier, Pascal Borry, David Geerts
- Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study(2023)
Authors: David Geerts, Koen Yskout, Stef Verreydt, Pascal Borry, Liese Barbier, Isabelle Huys
- How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys
- Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance(2023)
Authors: Liese Barbier
Pages: 801 - 817 - Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group(2023)
Authors: Rosanne Janssens, Isabelle Huys, Liese Barbier
- Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study(2023)
Authors: Evelien De Sutter, Pascal Borry, Isabelle Huys, Liese Barbier
- How to select a best-value biological medicine? A practical model to support hospital pharmacists(2022)
Authors: Liese Barbier, Yannick Vandenplas, Isabelle Huys, Arnold Vulto
Pages: 2001 - 2011 - How to balance valuable innovation with affordable access to medicines in Belgium?(2022)
Authors: Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Evelien De Sutter, Rosanne Janssens, Teodora Lalova-Spinks, Robbe Saesen, et al.
- Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking(2022)
Authors: Liese Barbier, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- When Will American Patients Start Benefitting From Biosimilars?(2022)
Authors: Arnold Vulto, Liese Barbier
Pages: 1044 - 1047